For Biotech VCs, Anticipation And Adjustments In The Age Of Earn-Outs
Executive Summary
The structured acquisition -- with contingent payments that stretch well beyond the close of the sale – is a permanent part of the biotech investor landscape. While it's certainly a buyer's market, the sellers have been adapting to help boost returns. Are their strategies working?